NYSE:JNJPharmaceuticals
Assessing Johnson & Johnson (JNJ) Valuation After Fresh FDA Wins In Rare Disease And Neuropsychiatry
Johnson & Johnson (JNJ) stock is drawing fresh attention after the FDA granted Priority Review to IMAAVY for warm autoimmune hemolytic anemia and approved a new CAPLYTA label for relapse prevention in schizophrenia.
See our latest analysis for Johnson & Johnson.
Despite a series of recent FDA milestones and product updates across rare disease and neuropsychiatry, Johnson & Johnson’s 30 day share price return of 7.75% and 90 day share price return of 3.82% suggest fading short term momentum,...

